Top of this page
Skip navigation, go straight to the content

bimekizumab - UCB4940

Disease area
studied
Abbreviated title Phase Study ID Registry database Study results Study summary Publication (if available)
Ankylosing Spondylitis  A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis Phase 2  AS0008

Ongoing
NCT02963506
2016-001102-42
Ankylosing Spondylitis   A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis Phase 2  AS0009
Ongoing
NCT03355573 2017-001002-15
Ankylosing Spondylitis Study to evaluate the efficacy and safety of Bimekizumab compared to Certolizumab Pegol in the treatment of subjects with active ankylosing spondylitis (AS) Phase 2 AS0013
Ongoing
NCT03215277
Hidradenitis Suppurativa  A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. HS0001
Ongoing
NCT03248531
Psoriatic Arthritis A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis Phase 2 PA0008
Completed
NCT02969525
2016-001103-23
 Psoriatic Arthritis  A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis Phase 2  PA0009
Ongoing
NCT03347110 2017-001003-74
Chronic Plaque Psoriasis This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO). Phase 3 PS0008
Ongoing
NCT03412747
Chronic Plaque Psoriasis A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate toSevere Chronic Plaque Psoriasis (BE VIVID) Phase 3 PS0009
Ongoing
Chronic Plaque Psoriasis Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients with Chronic Plaque Psoriasis
Phase 2 PS0010
Completed
NCT02905006

LINK
Papp K.A., et al. J Am Acad Dermatol 2018; 79(2):277–286
Chronic Plaque Psoriasis A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis Phase 2 PS0011
Ongoing
NCT03010527
Chronic Plaque Psoriasis
Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.
Phase 3 PS0013 
Ongoing
NCT03410992
Chronic Plaque Psoriasis A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 3 PS0015
Ongoing
NCT03536884
Chronic Plaque Psoriasis A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2 PS0016 
Completed
NCT03025542 2016-002368-15
Chronic Plaque Psoriasis  A Multicenter, 48-week, Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. Phase 2 PS0018
Ongoing
NCT03230292 2016-002934-57
Rheumatoid arthritis Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis Phase 2 RA0123
Completed
NCT02430909
2014-003307-30
 
Ulcerative Colitis A study to test the effectiveness of bimekizumab as a treatment for ulcerative colitis to look for
unwanted side effects and to measure how the drug is distributed, modified and cleared from the body.
Phase 2 UC0011
Terminated

2016-000420-26